Preferred physical characteristics of lidocaine thin film for women with vestibulodynia

Introduction Vestibulodynia (VBD) is the most common cause of sexual pain in the United States, affecting up to 15% of reproductive-aged women during their lifetime with limited treatment options. The purpose of this study was to describe ideal physical characteristics of a vulvar film designed for insertional sexual pain in sexually active women with VBD. Methods Twenty women were recruited to participant in one of six, semi-structured 60-minute focus group discussions regarding treatment options for VBD. Heterosexual women, aged 18–51 years old with a diagnosis of vulvodynia, vestibulodynia or insertional dyspareunia fit the inclusion criteria. Those who reported no episodes of vaginal intercourse in the prior 18 months were excluded. A new vulvar film technology loaded with 50 mg of 5% lidocaine was introduced to the group. Participants took part in focus groups on a rolling basis depending on availability. Focus group discussions were audio-recorded and transcribed verbatim. Two study investigators coded the transcripts using inductive coding and merged their respective projects to resolve disagreements. We analyzed data related to each code to develop code clusters and higher-level primary topics regarding device preferences. Data related to each of these primary topics was analyzed to assess the range of participant attitudes and preferences and to identify patterns within each primary topic. Results One hundred and sixteen women were recruited, and twenty women were enrolled. The mean age for the participants was 33.3 years. Most women were educated with at least some college (93%), White (78.6%), married (75%), and had income greater than $100,000 (50%). Analysis of the focus group discussions identified five common topics addressed by participants: desired loaded medication, film size, film shape, film flexibility, and ease and accuracy of use. Concerns across topics included comfort, sexual spontaneity, and efficacy. Interest in loading the device with other acceptable medications or combination with lidocaine was independently noted in 2/6 (33%) of the focus groups. Discussion Mucoadhesive vulvar thin films may be an acceptable drug delivery system for insertional sexual pain for women with VBD.

[1]  B. McFarlin,et al.  Evaluation and Treatment of Vulvodynia: State of the Science. , 2022, Journal of midwifery & women's health.

[2]  P. Lytsy,et al.  Treatment of Provoked Vulvodynia: A Systematic Review. , 2022, The journal of sexual medicine.

[3]  M. Çulha,et al.  Exclusive manual perineal rehabilitation with lidocaine 2% gel in the treatment of provoked vestibulodynia: results from a single-arm interventional study , 2022, International Journal of Impotence Research.

[4]  H. Joffe,et al.  From Challenge to Opportunity: Virtual Qualitative Research During COVID-19 and Beyond , 2022, International journal of qualitative methods.

[5]  Rima Janusziewicz,et al.  A mucoadhesive biodissolvable thin film for localized and rapid delivery of lidocaine for the treatment of vestibulodynia. , 2021, International journal of pharmaceutics.

[6]  M. Goetsch,et al.  Comparing Vestibule Examination Techniques: Light Touch, Serial Forces, and the Lidocaine Test , 2021, Journal of lower genital tract disease.

[7]  V. Barnabei Vulvodynia. , 2020, Clinical obstetrics and gynecology.

[8]  S. Bergeron,et al.  Vulvodynia , 2020, Nature Reviews Disease Primers.

[9]  J. Bornstein,et al.  Systematic review and meta-analysis of the effects of treatment modalities for vestibulodynia in women , 2019, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[10]  J. C. Rosa e Silva,et al.  Current usage of qualitative research in female pelvic pain: a systematic review , 2019, Archives of Gynecology and Obstetrics.

[11]  Deanne M. Taylor,et al.  Effect of gabapentin on sexual function in vulvodynia: a randomized, placebo‐controlled trial , 2019, American journal of obstetrics and gynecology.

[12]  Aulus Gellius XXIII , 2018, Aulus Gellius: Noctes Atticae.

[13]  A. Rapkin,et al.  Patterns in Vulvodynia Treatments and 6-Month Outcomes for Women Enrolled in the National Vulvodynia Registry-An Exploratory Prospective Study. , 2018, The journal of sexual medicine.

[14]  G. Moseley,et al.  Clinical assessment of the impact of pelvic pain on women , 2017, Pain.

[15]  Judy C. Chang,et al.  Preferred Physical Characteristics of Vaginal Film Microbicides for HIV Prevention in Pittsburgh Women , 2016, Archives of Sexual Behavior.

[16]  C. Dumoulin,et al.  011 Efficacy of Multimodal Physiotherapy Treatment Compared to Overnight Topical Lidocaine in Women with Provoked Vestibulodynia: A Bi-center Randomized Controlled Trial , 2016 .

[17]  L. Meyn,et al.  A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film , 2016, Journal of acquired immune deficiency syndromes.

[18]  H. S. Johal,et al.  Advanced topical drug delivery system for the management of vaginal candidiasis , 2016, Drug delivery.

[19]  Giuseppina Sandri,et al.  Mucoadhesive and thermogelling systems for vaginal drug delivery. , 2015, Advanced drug delivery reviews.

[20]  M. Patton Qualitative Research & Evaluation Methods: Integrating Theory and Practice , 2014 .

[21]  J. Martinez-de-Oliveira,et al.  Vaginal films for drug delivery. , 2013, Journal of pharmaceutical sciences.

[22]  Greg Dimitriadis,et al.  Focus Groups: From structured interviews to collective conversations , 2013 .

[23]  Lizheng Shi,et al.  Economic burden and quality of life of vulvodynia in the United States , 2012, Current medical research and opinion.

[24]  A. Nel,et al.  Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. , 2011, Journal of women's health.

[25]  J. Clarke,et al.  What is a systematic review? , 2011, Evidence Based Nursing.

[26]  J. Paavonen,et al.  Surgical treatment of vulvar vestibulitis: a review , 2010, Acta obstetricia et gynecologica Scandinavica.

[27]  Johnny Saldaña,et al.  The Coding Manual for Qualitative Researchers , 2009 .

[28]  D. Gorenflo,et al.  Treatment of Vulvodynia with Tricyclic Antidepressants: Efficacy and Associated Factors , 2006 .

[29]  K. Hartmann,et al.  Overnight 5% Lidocaine Ointment for Treatment of Vulvar Vestibulitis , 2003, Obstetrics and gynecology.

[30]  G. Green,et al.  Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. , 2001, Social science & medicine.

[31]  D. Cook,et al.  Users' guides to the medical literature: XXIII. Qualitative research in health care A. Are the results of the study valid? Evidence-Based Medicine Working Group. , 2000, JAMA.

[32]  M. Lorentzon Doing Qualitative Research , 1993 .

[33]  K. Heaton Pelvic pain in women. , 1986, British medical journal.

[34]  W. I. van der Meijden,et al.  Generalized unprovoked vulvodynia; A retrospective study on the efficacy of treatment with amitriptyline, gabapentin or pregabalin. , 2018, European journal of obstetrics, gynecology, and reproductive biology.

[35]  C. Slovis,et al.  State of the Science , 2009 .

[36]  D. Gorenflo,et al.  Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors. , 2006, Journal of lower genital tract disease.

[37]  B. Harlow,et al.  A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? , 2003, Journal of the American Medical Women's Association.

[38]  J. Galloway A Review of the , 1901 .